XSHE
002693
Market cap563mUSD
Oct 09, Last price
9.80CNY
1D
7.69%
1Q
-6.22%
Jan 2017
-9.09%
IPO
17.76%
Name
Hainan Shuangcheng Pharmaceuticals Co Ltd
Chart & performance
P/E
213.41
P/S
14.68
EPS
0.05
Div yield, %
—
Shrs. gr., 5y
0.23%
Rev. gr., 5y
-2.88%
Revenues
277m
+58.87%
Net income
19m
P
CFO
61m
P
Dividend
Mar 10, 20150.15 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Hainan Shuangcheng Pharmaceuticals Co., Ltd. operates internationally, undertaking the entire lifecycle of synthetic peptide drugs and active pharmaceutical ingredients (APIs), from initial research and development through manufacturing to global market distribution. Its extensive product portfolio encompasses a wide array of injectable medications, including somatostatin, thymosin, clindamycin hydrochloride, thymopentin, L-carnitine, uranin hydrobromide, inosine, cyclophosphine adenosine, motidine, scopolamine, and sodium ferulate. Additionally, the company provides vitamin B6. Founded in 2000, the firm is headquartered in Haikou, People's Republic of China.
Key people
Chief Financial Officer
Yixiang Ai
Deputy General Manager · since 2023
Yuan Li
Deputy General Manager · since 2023
Haiyan Li
Chief Human Resources Officer, Deputy General Manager · since 2023
Shiying Wang
Deputy General Manager · since 2023
Rui Wang
Deputy General Manager, Chief Analysis Officer · since 2023
Zhong Yao
Deputy General Manager · since 2023
Jianlin Yuan
Deputy General Manager · since 2023
Xiaofeng Yu
Secretary of the Board, Deputy General Manager · since 2010
Jianming Li
General Manager, Director · since 2019
Chengdong Wang
Chairman of the Board · since 2017
Yingpu Wang
Vice Chairman of the Board · since 2014
Jianwei Li
Independent Director · since 2023
Jianhua Xiao
Independent Director · since 2023
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||